Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for right ventricular function in non-diabetic COPD patients
IRCT20240707062351N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of empagliflozin in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Changes in echocardiography criteria, Changes in COPD attacks and 2 more. Started Sep 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on IRCT20240707062351N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240707062351N1.